Each CHF patient was classified according to appropriateness for palliative care against a definition of unresolved pain and/or symptoms and/or psychosocial problems 7 days post admission. Results Three hundred and sixty-five patient files were reviewed, and 28 clinically identified as having CHF. Of these, 11 had confirmed
unpreserved ejection fraction,16 of the 28 patients were appropriate for palliative care. Of the total inpatient population reviewed, 10 (2.7%) had both confirmed Inhibitors,research,lifescience,medical ejection fraction ≤45%, and were appropriate for palliative care. Of the 17 clinically-identified CHF patients with no recorded evidence of ejection fraction ≤45%, 5 (29.4%) were still appropriate for palliative care. A total of 4.4% of the reviewed inpatient population had a clinical diagnosis of CHF and were appropriate for palliative care. Conclusion CHF patients with ejection fraction >45% also require palliative care. Our conservative criteria suggest a point prevalence of 2.7% of patients having both ejection fraction Inhibitors,research,lifescience,medical Inhibitors,research,lifescience,medical ≤45% and palliative care needs, although this may be a conservative estimate due to the file review methodology to identify unresolved palliative care problems. It is important to note that the point prevalence of patients with clinical diagnosis and palliative care needs was 4.4% of the population. We present evidence-based
referral criteria from the larger multi methods study. Background End stage Chronic Inhibitors,research,lifescience,medical Heart Failure (CHF) is associated with high pain and symptom burden (e.g. 60–88% breathlessness, 42–82% fatigue, 41–77% pain, 17–48% nausea)[1,2] and mortality rates are poor among those newly diagnosed with heart failure (70% survival at 6 months
and 57% at 18 months).  The majority of admissions (72%) are unplanned,  and around one half of CHF patients die suddenly rather than dying of progressive Inhibitors,research,lifescience,medical heart failure.  As new treatments extend the Quizartinib unpredictable chronic disease phase, both the incidence and prevalence of chronic heart failure (CHF) are predicted to rise substantially.  Patients with CHF should be treated throughout the entire disease trajectory, and the National Institute for Clinical Mephenoxalone Excellence (NICE) CHF clinical guidance requires that ‘The palliative needs of patients and carers should be identified, assessed and managed at the earliest opportunity ‘. The aim of palliative care is to clinically manage complex (and often apparently refractory) symptoms, provide psycho-social support to the patient and their family, to improve quality of remaining life, achieve the best possible death, and should be available from the point of diagnosis through to the end of life.  However, there is currently no data to model the magnitude of palliative care provision required to meet guidance requirements.